Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as gliob… Read more
Lantern Pharma Inc (LTRN) - Total Liabilities
Latest total liabilities as of September 2025: $4.04 Million USD
Based on the latest financial reports, Lantern Pharma Inc (LTRN) has total liabilities worth $4.04 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lantern Pharma Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Lantern Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lantern Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Lantern Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Done.ai Group AB
ST:DONE
|
Sweden | Skr232.15 Million |
|
Elliptic Laboratories AS
OL:ELABS
|
Norway | Nkr25.74 Million |
|
Cibl Inc.
PINK:CIBY
|
USA | $629.00K |
|
Faze Three Limited
NSE:FAZE3Q
|
India | ₹3.29 Billion |
|
Everbright Digital Holding Limited Ordinary Shares
NASDAQ:EDHL
|
USA | $532.65K |
|
Incheon City G
KO:034590
|
Korea | ₩203.50 Billion |
|
Oriental Interest Bhd
KLSE:5827
|
Malaysia | RM931.03 Million |
|
Hexza Corporation Bhd
KLSE:3298
|
Malaysia | RM18.24 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Lantern Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lantern Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lantern Pharma Inc (2018–2024)
The table below shows the annual total liabilities of Lantern Pharma Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.38 Million | +60.02% |
| 2023-12-31 | $2.74 Million | -2.09% |
| 2022-12-31 | $2.80 Million | +17.62% |
| 2021-12-31 | $2.38 Million | +260.01% |
| 2020-12-31 | $660.84K | +35.06% |
| 2019-12-31 | $489.29K | -24.91% |
| 2018-12-31 | $651.63K | -- |